These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35190697)

  • 1. Puerarin-V prevents the progression of hypoxia- and monocrotaline-induced pulmonary hypertension in rodent models.
    Chen D; Zhang HF; Yuan TY; Sun SC; Wang RR; Wang SB; Fang LH; Lyu Y; Du GH
    Acta Pharmacol Sin; 2022 Sep; 43(9):2325-2339. PubMed ID: 35190697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvianolic acid A attenuates vascular remodeling in a pulmonary arterial hypertension rat model.
    Chen YC; Yuan TY; Zhang HF; Wang DS; Yan Y; Niu ZR; Lin YH; Fang LH; Du GH
    Acta Pharmacol Sin; 2016 Jun; 37(6):772-82. PubMed ID: 27180980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artemisinin and Its Derivate Alleviate Pulmonary Hypertension and Vasoconstriction in Rodent Models.
    Bao C; He Q; Wang H; Sun Y; Xu Y; Pan Y; Hu Y; Zheng S; Liang S; Luo A; Nahar T; Chen J; Tang H; Han Y
    Oxid Med Cell Longev; 2022; 2022():2782429. PubMed ID: 35757500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Puerarin prevents progression of experimental hypoxia-induced pulmonary hypertension via inhibition of autophagy.
    Zhang X; Liu Q; Zhang C; Sheng J; Li S; Li W; Yang X; Wang X; He S; Bai J; Zhu D
    J Pharmacol Sci; 2019 Oct; 141(2):97-105. PubMed ID: 31640920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension.
    Christou H; Reslan OM; Mam V; Tanbe AF; Vitali SH; Touma M; Arons E; Mitsialis SA; Kourembanas S; Khalil RA
    Am J Physiol Lung Cell Mol Physiol; 2012 May; 302(9):L875-90. PubMed ID: 22287610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formononetin attenuates monocrotaline‑induced pulmonary arterial hypertension via inhibiting pulmonary vascular remodeling in rats.
    Cai C; Xiang Y; Wu Y; Zhu N; Zhao H; Xu J; Lin W; Zeng C
    Mol Med Rep; 2019 Dec; 20(6):4984-4992. PubMed ID: 31702810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
    Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
    Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
    Cheng G; Wang X; Li Y; He L
    Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of rutaecarpine on right ventriclar remodeling in rats with monocrotaline-induced pulmonary hypertension].
    Li XW; Wang XM; Li S; Yang JR
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2014 Sep; 30(5):405-10. PubMed ID: 25571629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension.
    Tofovic SP; Zhang X; Jackson EK; Dacic S; Petrusevska G
    Vascul Pharmacol; 2006 Dec; 45(6):358-67. PubMed ID: 16872912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble guanylate cyclase stimulator, trans-4-methoxy-β-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats.
    Gonzaga-Costa K; Vasconcelos-Silva AA; Rodrigues-Silva MJ; Rebouça CDSM; Duarte GP; Borges RS; Magalhães PJC; Lahlou S
    Eur J Pharmacol; 2021 Apr; 897():173948. PubMed ID: 33609564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.
    Comeglio P; Filippi S; Sarchielli E; Morelli A; Cellai I; Corno C; Adorini L; Vannelli GB; Maggi M; Vignozzi L
    J Endocrinol Invest; 2019 Aug; 42(8):951-965. PubMed ID: 30674010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of sesamin on pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary hypertension].
    Li XW; Gao YX; Li S; Yang JR
    Zhongguo Zhong Yao Za Zhi; 2015 Apr; 40(7):1355-61. PubMed ID: 26281561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
    Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats.
    Zhao C; Hu L; He X; Li L; Yin M; Tettey AT; Wang Y; Shen J; Tang S; Wu C; Li Q; Wang Z; Li X
    Vascul Pharmacol; 2022 Aug; 145():107017. PubMed ID: 35680060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary Artery Hypertension Model in Rats by Monocrotaline Administration.
    Bueno-Beti C; Sassi Y; Hajjar RJ; Hadri L
    Methods Mol Biol; 2018; 1816():233-241. PubMed ID: 29987824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged inhaled NO attenuates hypoxic, but not monocrotaline-induced, pulmonary vascular remodeling in rats.
    Horstman DJ; Frank DU; Rich GF
    Anesth Analg; 1998 Jan; 86(1):74-81. PubMed ID: 9428855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension.
    Nave AH; Mižíková I; Niess G; Steenbock H; Reichenberger F; Talavera ML; Veit F; Herold S; Mayer K; Vadász I; Weissmann N; Seeger W; Brinckmann J; Morty RE
    Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1446-58. PubMed ID: 24833797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib alleviates experimental pulmonary arterial hypertension.
    Kim SY; Lee JH; Huh JW; Kim HJ; Park MK; Ro JY; Oh YM; Lee SD; Lee YS
    Am J Respir Cell Mol Biol; 2012 Nov; 47(5):698-708. PubMed ID: 22842494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Astragaloside IV blocks monocrotaline‑induced pulmonary arterial hypertension by improving inflammation and pulmonary artery remodeling.
    Jin H; Jiao Y; Guo L; Ma Y; Zhao R; Li X; Shen L; Zhou Z; Kim SC; Liu J
    Int J Mol Med; 2021 Feb; 47(2):595-606. PubMed ID: 33416126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.